» Acromegaly and Neuroendocrine Tumours Global Survey

We are pleased to announce that the findings from our recent acromegaly and NETs global survey have been published in Advances in Therapy, in the paper titled:

Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours

The scientific committee surveyed patients, HCPs and non-HCP caregivers to assess current opinion surrounding SRL device attributes associated with the most favourable injection experience for people living with acromegaly and neuroendocrine tumours (NETs).

The findings identify the key features of injection devices for SRL therapy and underscore the importance of involving patients in treatment decisions.

Read the publication, download the survey overview and get the key clinical takeaways below.

Clinical Takeaways

Attributes that significantly impact the treatment experience for both patients and caregivers include ease and confidence of device use, device safety with a focus on minimising contamination risks and less burdensome injections
The survey underscores the need to boost confidence in administering SRL injections for non-HCP caregivers and self-injecting patients. Achieving this involves device-specific training, patient education, instructional videos, online resources, and continued support from HCPs
Patient and caregiver opinions play a crucial role in advancing device design, enabling shared decision-making, and selecting suitable injection devices tailored to individual therapeutic requirements